1. Wingo, PA, Calle EE, McTiernan A. How does breast cancer mortality compare with that of other cancers and selected cardiovascular diseases at different ages in U.S. women?. J Womens Health Gend Based Med. 2000;9(9):999-1006. [
Link] [
DOI:10.1089/15246090050200033] [
PMID]
2. Kannel, WB, Wilson PW. Risk factors that attenuate the female coronary disease advantage. Arch Intern Med. 1995;155(1):57-61.
https://doi.org/10.1001/archinte.1995.00430010063008 [
Link] [
DOI:10.1001/archinte.155.1.57] [
PMID]
3. Santoro N, Randolph JF Jr. Reproductive hormones and the menopause transition. Obstet Gynecol Clin North Am. 2011;38(3):455-66. [
Link] [
DOI:10.1016/j.ogc.2011.05.004] [
PMID] [
PMCID]
4. Hodis HN, Mack WJ. Coronary heart disease and hormone replacement therapy after the menopause. Climacteric. 2009;12(Suppl 1):71-5. [
Link] [
DOI:10.1080/13697130903095178] [
PMID]
5. Alexandersen P, Karsdal MA, Christiansen c. Long-term prevention with hormone-replacement therapy after the menopause: Which women should be targeted?. Womens Health (Lond). 2009;5(6):637-47. [
Link] [
DOI:10.2217/WHE.09.52] [
PMID]
6. Mendelsohn ME. Protective effects of estrogen on the cardiovascular system. Am J Cardiol. 2002;89(12A):12E-17E. [
Link] [
DOI:10.1016/S0002-9149(02)02405-0]
7. Kuttenn F, Gerson M. Hormone replacement therapy of menopause, heart and blood vessels. Arch Mal Coeur Vaiss. 2001;94(7):685-9. [French] [
Link] [
PMID]
8. Schaefer EJ, Genest JJ Jr, Ordovas JM, Salem DN, Wilson PW. Familial lipoprotein disorders and premature coronary artery disease. Atherosclerosis. 1994;108 Suppl:S41-S54. [
Link] [
DOI:10.1016/0021-9150(94)90152-X]
9. Gofman JW, Delalla O, Glazier F, Freeman NK, Lindgren FT, Nichols AV, et al. The serum lipoprotein transport system in health, metabolic disorders, atherosclerosis and coronary heart disease. J Clin Lipidol. 2007;1(2):104-41. [
Link] [
DOI:10.1016/j.jacl.2007.03.001] [
PMID]
10. Jonas HA, Kronmal RA, Psaty BM, Manolio TA, Meilahn EN, Tell GS, et al. Current estrogen-progestin and estrogen replacement therapy in elderly women: Association with carotid atherosclerosis, CHS Collaborative Research Group, Cardiovascular Health Study. Ann Epidemiol. 1996;6(4):314-23. [
Link] [
DOI:10.1016/S1047-2797(96)00048-8]
11. Cziraky MJ, Watson KE, Talbert RL. Targeting low HDLcholesterol to decrease residual cardiovascular risk in the managed care setting. J Manag Care Pharm. 2008;14(8 Suppl):S3-28. [
Link] [
PMID]
12. Suk Danik J, Rifai N, Buring JE, Ridker PM. Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events. J Am Coll Cardiol. 2008;52(2):124-31. [
Link] [
DOI:10.1016/j.jacc.2008.04.009] [
PMID] [
PMCID]
13. Urabe M, Yamamoto T, Kashiwagi T, Okubo T, Tsuchiya H, Iwasa K, et al. Effect of estrogen replacement therapy on hepatic triglyceride lipase, lipoprotein lipase and lipids including apolipoprotein E in climacteric and elderly women. Endocr J. 1996;43(6):737-42. [
Link] [
DOI:10.1507/endocrj.43.737]
14. Wagner JD, Martino MA, Jayo MJ, Anthony MS, Clarkson TB, Cefalu WT. The effects of hormone replacement therapy on carbohydrate metabolism and cardiovascular risk factors in surgically postmenopausal cynomolgus monkeys. Metabolism, 1996;45(10):1254-62. [
Link] [
DOI:10.1016/S0026-0495(96)90244-9]
15. Sack MN, Rader DJ, Cannon RO 3rd. Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women. Lancet, 1994;343(8892):269-70. [
Link] [
DOI:10.1016/S0140-6736(94)91117-7]
16. Cressman MD, Heyka RJ, Paganini EP, O'Neil J, Skibinski CI, Hoff HF. Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation. 1992;86(2):475-82. [
Link] [
DOI:10.1161/01.CIR.86.2.475] [
PMID]